Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Crown Bioscience Inc. Announcing the 2017 Board of Directors Election Results

Crown Bioscience Inc.
Posted on: 09 Nov 17
Dr. Guoliang Yu re-elected as the Chairman

TAIPEI, Taiwan, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has held an extraordinary general meeting and announced results of stockholder elections for the company's 2017 Board of Directors. Dr. Guoliang Yu was re-elected as Chairman of the Board.

The elected Board of Directors comprise global experts and industry leaders from venture capital, corporate management, biotechnology and corporate governance. The complete list of elected directors is as follows:

Dr. Guoliang Yu, Director, Chairman of Board, re-elected
Mr. Sandy Chau, Director, re-elected
Mr. Chen-Chi Kai, Director, re-elected
Dr. Hongbo Lu, Director, re-elected
Dr. Jo Shen, Independent Director, re-elected
Dr. George Lee, Independent Director, re-elected
Mr. Wu-Fu Chen, Director, newly-elected
Mr. Andrew Lin, Independent Director, newly-elected
Dr. Jean-Pierre Wery, Director, newly-elected

The newly elected Director Mr. Wu-Fu Chen received his Master of Electrical Engineering degree from University of Florida and later completed his Ph.D. in Computer Science at University of California, Berkeley. He began his entrepreneur journey from Silicon Valley and was named "The Top 10 Entrepreneur of 2000", "The Germinator", and "The Top 100 Venture Investors in the US of 2002". Mr. Wu currently served as the Chairman of Acorn Venture Capitals and is well known for his success in capital investments.

The newly elected Director Mr. Andrew Lin received his MBA degree from the University of Chicago and later completed a Master of Electrical and Computer Engineering degree at Massachusetts Institution of Technology. He is well recognized for his professional expertise in securities studies, investment banking, corporate management, and strategy consulting. Mr. Lin currently serves as the Chairman of Lotus Pharmaceutical and Independent Director of Fubon Life Insurance.

The newly elected Director Dr. Jean-Pierre Wery, is CEO of Crown Bioscience. Dr. Wery has been working for the company since 2008 and was appointed as CEO in 2016.  He received his Ph.D. in Physics at Université de Liège and completed his postdoctoral studies at Purdue University.

The elected Board will serve a three year term. The three Independent Directors Jo Shen, George Lee, and Chun Lin will serve as the members of Audit and Compensation Committees. The shareholder voting participating rate is close to 70% and the major shareholders include OrbiMed Healthcare Fund Management, Lilly Asia Ventures, and Center Laboratories.

About Crown Bioscience Inc.

Crown Bioscience  is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. 
marketing@CrownBioscience.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Crown Bioscience Inc. via GlobeNewswire
HUG#2148561
GlobeNewswire
globenewswire.com

Last updated on: 10/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.